Under the US Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? In a podcast episode of Our Curious Amalgam, titled “Biologically similar but competitively not so? Economic considerations of IP litigation settlements involving biosimilars” Sean Sheridan and Archan Ruparel speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more.
ASCO 2024 review: The benefits and barriers of biomarkers in oncology
Biomarkers: what do we mean? – The term “biomarkers” can be broadly clustered into four categories: molecular, histologic, radiographic and physiological. –...